Major advances in the diagnosis and treatment of non-small cell lung cancer (NSCLC) have
resulted in a sharp decline in associated mortality rates, thereby propelling NSCLC to the …

Abstract Objectives According to 2018 United States and international lung cancer and
pathology guidelines, testing of EGFR, ALK, ROS1 and BRAF genes is a minimum …

In advanced non-small cell lung cancer (NSCLC), patients with actionable genomic
alterations may derive additional clinical benefit from targeted treatment compared to …

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Simple Summary In the field of non-small cell lung cancer (NSCLC), there have been
significant advancements in genomic data and bioinformatics tools, which have improved …

Abstract Background. The National Comprehensive Cancer Network (NCCN) guidelines for
patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR …

Non–small cell lung cancer (NSCLC) has become a prominent example of precision
medicine among solid tumor malignancies. Clinical management of NSCLC now depends …

Precision medicine is essential for the modern care of a patient with cancer. Comprehensive
molecular profiling of the tumor itself is necessary to determine the presence or absence of …

Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …

Worldwide, lung cancer is the most prevalent form of cancer, and its non–small-cell subtype
constitutes up to 85% of cases. Overall, lung cancer is the most common cause of cancer …